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During the course of a molecular epidemiology study of mechanisms of antibiotic resistance in the area
served by our hospital (516,000 inhabitants), we isolated the gene encoding CTX-M-14 -lactamase. Thirty
clinical strains (27 Escherichia coli and 3 Klebsiella pneumoniae isolates) with a phenotype of extended-spectrum
-lactamase were collected from January to October 2001 and studied for the presence of the CTX-M-14 -
lactamase gene. By isoelectric point determination, PCR, and nucleotide sequencing, we detected the presence
of this gene in 17 E. coli strains belonging to 15 different genotypes (REP-PCR) causing infections in 17
different patients. Epidemiological studies based on medical records did not suggest any relationship be-
tween the patients infected with these E. coli strains and, interestingly, 7 of 30 patients harboring strains with
extended-spectrum -lactamases never had contact with the hospital environment before the clinical E. coli
isolation. Conjugation experiments revealed that this gene was plasmid mediated in the 17 E. coli strains, and
plasmid restriction fragment length polymorphisms showed 9 different patterns in the 17 E. coli strains. By
PCR, the sequence of the tnpA transposase gene of the insert sequence ISEcp-1 was detected in all the plasmids
harboring the CTX-M-14 gene. These results strongly suggest that plasmid dissemination between different
E. coli strains in addition to a mobile element (transposon) around the -lactamase gene may be involved in
the spreading of the CTX-M-14 gene. This study reinforces the hypothesis that the epidemiology of the prev-
alence of the -lactamase genes is changing and should alert the medical community to the increase in the
emergence of the CTX-M -lactamases worldwide.
The emergence of plasmid-mediated extended-spectrum
-lactamases (ESBLs) in members of the family Enterobacte-
riaceae has become a worldwide problem (6, 12, 21). ESBL
molecular class A possesses an extended hydrolysis spectrum
toward oxyimino--lactams and aztreonam but remains sus-
ceptible to cefoxitin and -lactamase inhibitors (7). Most
ESBLs are derivatives of TEM-1, TEM-2, or SHV-1 enzymes;
however, reports describing the emergence of -lactamases
belonging to other families, such as CTX-M and/or OXA de-
rivatives, are increasing worldwide (5, 8, 10, 11, 16).
CTX-M-related enzymes have been found in Europe, South
America, and Mediterranean countries (3, 13, 15, 16, 18, 21).
Unlike microorganisms harboring TEM and SHV -lacta-
mases, reports of outbreaks caused by organisms harboring
non-TEM or non-SHV ESBL are very scarce. CTX-M-14
-lactamase has recently been described in clinical isolates in
Korea, China, and France (8, 11, 16, 19). In this communica-
tion we not only report for the first time the presence of the
CTX-M-14 gene in Spain but we also show clear evidence of
the dissemination of the gene encoding CTX-M-14 among 17
different patients, who had no apparent contact, living in the
northwest part of Spain. This CTX-M-14 gene was detected in
15 different genotypes of Escherichia coli strains causing uri-
nary tract infection in 17 patients in an area of 516,000 inhab-
itants. Plasmid dissemination and the presence of a putative
transposon around the CTX-M-14 gene may account for the
spreading of this gene. This finding emphasizes the increasing
role of the CTX-M -lactamases in antibiotic resistance world-
wide and leads to consideration of empirical treatment for
infections caused by E. coli strains, especially in patients com-
promised by underlying disease or immunological status.
MATERIALS AND METHODS
Selection of clinical isolates and patients. Between January and October 2001,
27 E. coli and 3 Klebsiella pneumoniae clinical strains with an ESBL phenotype
were collected in the Department of Microbiology, Juan Canalejo Hospital, a
1,200-bed hospital serving a population of 516,000 in the northwest area of Spain.
These isolates were identified by DadeMicroScan and the API 20E system
(bioMe´rieux, Marcy l’Etoile, France).
Susceptibility tests and confirmation of ESBL production. The MICs of the
-lactams were determined by using E-test strips (AB Biodisk, Dalva¨gen, Swe-
den). The ESBL phenotype was detected by using ESBL detection E-test strips
(AB Biodisk) as specified by the manufacturer. The double disk diffusion test was
concomitantly used to confirm the E-test results.
IEF assay. -Lactamases were characterized by isoelectric focusing (IEF) of
ultrasonicated bacterial extracts. Bacteria growing exponentially at 37°C in Lu-
ria-Bertani (LB) medium were harvested, and cell-free lysates were prepared by
sonication. -Lactamases were analyzed by isoelectric focusing of cell extracts on
polyacrylamide gels containing ampholytes with a pH range of 3 to 9 (PhastGel;
Amersham Pharmacia Biotech AB) in a PhastSystem apparatus (Amersham
Pharmacia Biotech AB). The focused -lactamases were detected by overlaying
the gel with nitrocefin (0.5 mg/ml) in 100 mM phosphate buffer (pH 7.0). pIs
were determined by comparison with those of -lactamases with a known pI:
TEM-1 (pI 5.4), SHV-1 (pI 7.6), IMP-2 (pI 8.2), and AmpC from A. baumannii
(pI 9.4).
DNA extraction. Bacterial chromosomal DNA was obtained with the High
Pure PCR template preparation kit (Roche Diagnostics Corp., Indianapolis,
Ind.). The chromosomal DNA was checked by electrophoresis in agarose gels,
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and the concentrations of the different extracts were standardized by spectro-
photometric measurements.
Conjugation experiments, plasmid purification, cloning experiments, and
DNA sequencing. Transfer of resistance by conjugation was attempted using
E. coli BM21 and E. coli XL-10-Gold Kan cells (Stratagene, La Jolla, Calif.) as
recipients. Overnight mating experiments were performed at 37°C, and the
transconjugants were selected on LB agar plates supplemented with ampicillin
(50 g/ml) and nalidixic acid (50 g/ml) for E. coli BM21 and ampicillin (50
g/ml) and kanamycin (25 g/ml) for E. coli XL-10-Gold Kan cells. Afterward,
transconjugants were selected for the cefotaxime resistance phenotype.
Plasmids from different E. coli strains were purified by the alkaline-lysis
method with the High Pure plasmid isolation kit (Roche Diagnostics Corp.).
Cloning procedures were performed as described by Sambrook et al. (20). Re-
striction enzymes were purchased from Boehringer (Mannheim, Germany) and
were used as specified by the manufacturer.
For cloning the CTX-M-14 gene, plasmid DNA from transconjugant E. coli
clinical strain 3 (see Table 2) was digested with BamHI. The resulting fragments
were ligated into pBGS18 and digested with BamHI, and the mixture was trans-
formed into E. coli TG1 made competent by the calcium chloride method (20).
After transformation, a few clones grew on LB agar plates supplemented with
kanamycin (10 g/ml) and ampicillin (50 g/ml). They harbored an identical
plasmid (pC) with an insert of about 6 kb. These plasmids were used as tem-
plates to determine the nucleotide sequence. Templates were sequenced on both
strands by the method of Sanger et al. Sequencing was carried out with the Taq
DyeDeoxyTerminator cycle-sequencing kit using primers specific to the coding
sequence, and the sequence was analyzed in an automatic DNA sequencer (377
ABI Prism; Perkin-Elmer).
Detection of the CTX-M-14 gene. Plasmid DNA from different E. coli strains
was used as the template in a PCR amplification. Amplification reactions were
performed in a final volume of 50 l. Mg2-free PCR buffer was purchased as a
10 concentrate consisting of 500 mM KCl, 100 mM Tris-HCl (pH 9.0), and 1%
Triton X-100 (Perkin-Elmer, Roche Molecular Systems, Inc., Nutley, N.J.) with
200 M (each) dATP, dCTP, dGTP, and dTTP (Perkin-Elmer, Roche Molecular
Systems, Inc.). The Mg2 concentration was 2.5 mM, and the primers were used
at 0.5 M each. The primer pair CTX-M-1 (5-AACACGGATTGACCGTAT
TG-3) and CTX-M-2 (5-TTACAGCCCTTCGGCGAT-3) was used to amplify
the CTX-M-14 gene in the plasmid DNA. Amplification reactions were carried
out in an Eppendorf thermal cycler (Eppendorf AG, Hamburg, Germany), with
an initial denaturation (10 min at 94°C) followed by 30 cycles of denaturation (30
s at 94°C), annealing (30 s at 58°C), and extension (2 min at 72°C), with a single
final extension of 10 min at 72°C. Aliquots (15 l) of each sample were subjected
to electrophoresis in 1.0% agarose gels. Amplified products were detected after
staining with ethidium bromide (50 g/ml) and photographed with Polaroid type
665 film.
REP-PCR. Amplification reactions were performed in a final volume of 50 l.
Mg2-free PCR buffer was purchased as a 10 concentrate consisting of 500 mM
KCl, 100 mM Tris-HCl (pH 9.0), and 1% Triton X-100 (Perkin-Elmer, Roche
Molecular Systems, Inc.), with 200 M (each) dATP, dCTP, dGTP, and dTTP
(Perkin-Elmer, Roche Molecular Systems, Inc.). The Mg2 concentration was
3 mM, and the primers were used at 0.5 M each. The primer pair REP1 (5-
IIIGCGCCGICATCAGGC-3) and REP2 (5-ACGTCTTATCAGGCCTAC-
3) was used to amplify putative REP-like elements in the genomic bacterial
DNA (23). A total of 500 ng of chromosomal DNA was added to the reaction
mixture. Amplification reactions were carried out in an Eppendorf thermal
cycler, with an initial denaturation (10 min at 94°C) followed by 30 cycles of
denaturation (1 min at 94°C), annealing (1 min at 45°C), and extension (2 min at
72°C), with a single final extension of 16 min at 72°C. Aliquots (20 l) of each
sample were subjected to electrophoresis in 1.0% agarose gels. Amplified prod-
ucts were detected after staining with ethidium bromide (50 g/ml) and photo-
graphed with Polaroid type 665 film. Strains belonging to the same DNA group
showed identical or highly similar profiles (up to two bands different).
Plasmid restriction fragment length polymorphisms (RFLPs). Plasmid DNA
from transconjugant E. coli strains 1 to 17 (see Table 2) was isolated as described
above. The DNA was then digested with HindIII, and the resulting fragments
were loaded on a 0.8% agarose gel. After electrophoresis, DNA fragments were
detected by staining with ethidium bromide (50 g/ml) and photographed with
Polaroid type 665 film.
Detection of the gene encoding the tnpA transposase. To detect the presence
of the tnpA gene of the insert sequence ISEcp-1, we used the primer pair tnpa1
(5-GAATTCATCAATTGTATT-3) and tnpa2 (5-CAAGAAATACATACTT
CAA-3). About 10 ng of plasmid DNA was added to the reaction mixture.
Amplification reactions were carried out in an Eppendorf thermal cycler, with an
initial denaturation (10 min at 94°C), 30 cycles of denaturation (1 min at 94°C),
annealing (1 min at 48°C), and extension (2 min at 72°C), and a single final
extension of 16 min at 72°C. Aliquots (20 l) of each sample were subjected to
electrophoresis in 1.0 % agarose gels. Amplified products were detected after
staining with ethidium bromide (50 g/ml) and photographed with Polaroid type
665 film.
RESULTS
Selection of clinical isolates and patients. Between January
and October 2001, 27 E. coli and 3 K. pneumoniae clinical
strains with a phenotype suggestive of ESBL were selected.
These strains were isolated from 30 different patients. One
isolate per patient was selected (Table 1). The strains were
associated with urinary tract infections (77%), wound infection
(13.3%), catheter infection (3.3%), blood infection (3.3%),
and conjuntival infection (3.3%). Most patients had underlying
diseases. Moreover, although most of the patients were hospi-
talized before the E. coli and/or K. pneumoniae isolation, seven
patients had no hospital admission noted in their medical
records.
Determination of antibiotic susceptibility and ESBL pro-
duction. MICs for the 30 clinical strains were determined by
the DadeMicroScan. In addition, all MICs were confirmed by
the E test (AB Biodisk) according to the NCCLS criteria (14).
The overall results are shown in Table 2. For all strains, the
amoxicillin MICs were higher than 256 g/ml; moreover, this
concentration decreased drastically in the presence of clavu-
lanic acid, suggesting the presence of a class A -lactamase.
Regarding broad-spectrum cephalosporins, strains 1 to 17 and
22 had a phenotype suggesting cefotaximase -lactamase ac-
tivity as shown by the cefotaxime MICs (the cefotaxime MICs
were clearly higher than the ceftazidime MICs).
Interestingly, the K. pneumoniae isolates included in this
study with an ESBL phenotype (strains 28 to 30) showed
unique SHV-like -lactamase activity band by IEF. This band
probably corresponds to the SHV chromosomal -lactamase
that is consitutively present in K. pneumoniae strains; alterna-
tively, it is an SHV ESBL indistinguishable from the chromo-
somal SHV-1. The presence of a second antibiotic resistance
mechanism in these K. pneumoniae strains cannot be ruled out.
IEF assay. Protein extracts of the 30 clinical strains and their
transconjugants obtained by sonication were resolved by IEF
(3–9). Different pIs corresponding to different -lactamases
were obtained. Interestingly, strains 1 to 17 yielded an identical
pI of 8.0; in addition, some of them yielded a pI of 5.4, sug-
gestive of a TEM-1-like -lactamase. Strains 18 to 30 showed
different pIs such as 5.4, 5.9, 7.4, 7.6, 7.9, 8.5, and 9.0 (Table 2).
Cloning of the CTX-M-14 gene. The cefotaxime MICs and
pIs obtained by IEF suggested the presence of an identical or
similar -lactamase gene associated with resistance to cefo-
taxime in strains 1 to 17 (Table 2). We attempted to clone the
-lactamase gene responsible for this selective resistance to
cefotaxime.
For this purpose, strain 3 (Table 2) was chosen for the
cloning experiments. First, we tried to show whether the -lac-
tamase gene was plasmid or chromosomally mediated. A con-
jugation experiment was performed using E. coli XL-1-blue as
a host, as described in Materials and Methods. Transconju-
gants were selected on LB agar plates supplemented with
kanamycin and ampicillin. Several transconjugants were ob-
tained, and IEF of the sonicated extracts of the clinical strain
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and the transconjugants showed a pI 8.0 activity band in all
cases. Plasmid analysis of the clinical strain (strain 3) and one
transconjugant (strain 3Tc) showed that the -lactamase gene
was associated with a plasmid of ca. 40 kb (data not shown).
Moreover, MIC experiments performed with both parental
(strain 3) and transconjugant (strain 3Tc) isolates showed al-
most identical antibiotic susceptibilities (Table 2), clearly sug-
gesting that the -lactamase gene was plasmid mediated.
Cloning of the CTX-M-14 gene was performed as described
in Materials and Methods. The nucleotide sequence of the
fragment revealed only one open reading frame with homology
with -lactamase genes. The CTX-M-14 open reading frame
was 876 bp long and encoded a protein of 291 amino acid
residues. This gene has previously been reported (GenBank
accession numbers AJ416341 and AF252622). In the upstream
region of the CTX-M-14 gene, the nucleotide sequence of the
tnpA gene, the transposase gene of insertion sequence ISEcp1,
was also detected (24).
Spread of the CTX-M-14 gene in different E. coli strains. To
elucidate whether the CTX-M-14 gene was plasmid mediated
in all E. coli strains, conjugation experiments were performed.
Regarding the kanamycin and/or nalidixic acid susceptibility of
the E. coli clinical strains, two different E. coli isolates were
used as hosts in the conjugation experiments, E. coli BM21
(resistant to nalidixic acid) when the E. coli clinical strains were
susceptible to nalidixic acid and E. coli XL-10-Gold Kan (re-
sistant to kanamycin) when the E. coli clinical strains were
susceptible to kanamycin. Transconjugants were obtained in all
E. coli strains (isolates 1 to 17 in Table 2) that yielded a
-lactamase activity band of pI 8.0 with cefotaximase activity,
strongly suggesting that in all cases the -lactamase with cefo-
taximase activity was plasmid mediated.
To assess the possibility of the spread of this CTX-M-14
gene in the 16 remaining E. coli strains, a PCR assay was per-
formed. Plasmid DNA obtained from the 27 E. coli and 3
K. pneumoniae strains was used as a template in a PCR am-
plification with CTX-M-1 (5-AACACGGATTGACCGTA
TTG-3) and CTX-M-2 (5-TTACAGCCCTTCGGCGAT-3)
primers, which annealed at the promoter and the 3 part of the
CTX-M-14 gene, respectively. Interestingly, a positive PCR
result, indicated by a band of 905 bp, was detected in 17 out of
30 clinical strains, including strain 3 (data not shown). The
overall results showed that the CTX-M-14 gene was dissemi-
nated among 17 E. coli strains in the northwest area of Spain.
Moreover, nucleotide sequence analysis of these 17 amplicons
showed total identity to the CTX-M-14 nucleotide sequence.
It is worth mentioning that strain 18, although possessing a
pI 8.5 band of -lactamase activity, did not yield an amplifica-
tion product with the CTX-M-1 and CTX-M-2 primers. Also,
the antibiotic susceptibility pattern of this strain did not show
the putative cefotaximase profile detected in the other 17
E. coli strains.
The next step was to try to determine whether these 17
E. coli strains were genetically related. This experiment was
necessary to distinguish between two putative hypotheses: (i)
one epidemic E. coli strain has been disseminated among all




infectiona Underlying disease Specimen
Hospitalization before the
E. coli isolation
1. F/81 UTI Diabetes Urine No
2. F/9 UTI Acute pyelonephritis Urine Yes
3. M/66 UTI Prostate tumor Urine Yes
4. F/1 UTI Respiratory tract infection Urine Yes
5. F/Unknown UTI Unknown Urine Unknown
6. F/77 UTI Blood infection, diabetes Urine Yes
7. F/80 UTI No Urine No
8. F/Unknown UTI Unknown Urine Unknown
9. M/67 UTI Colon cancer Urine Yes
10. M/58 UTI Prostate tumor Urine Yes
11. F/73 UTI HBP,b arthrosis Urine Yes
12. F/75 UTI HPB, urinary incontinence Urine No
13. F/41 UTI Unknown Urine No
14. F/57 WI Stomach ulceration Exudate Yes
15. F/76 UTI Type II diabetes, chronic hepatitis Urine Yes
16. M/86 WI Unknown Exudate Unknown
17. F/37 UTI No Urine No
18. F/73 UTI HBP, subarachnoid hemorrhagia Urine Yes
19. F/32 UTI Unknown Urine Yes
20. F/51 UTI Unknown Urine Yes
21. F/73 UTI HBP Urine Yes
22. M/25 WI Unknown Exudate No
23. F/14 CI Unknown Catheter Unknown
24. M/79 WI Pneumonia Exudate Yes
25. F/66 UTI Unknown Urine No
26. M/73 UTI Prostate tumor Urine Yes
27. M/5 UTI Several UTIs Urine Yes
28. M/53 UTI Leukemia Urine Yes
29. F/1 BI Hepatitis Blood Yes
30. F/1 CoI Premature birth Conjunctival swab Yes
a UTI, urinary tract infection; WI, wound infection; CI, catheter infection; BI, blood infection; CoI, conjunctival infection.
b HBP, high blood pressure.
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the patients, and so one ancestor strain may be responsible for
the spreading; it implies a link between all the patients, and
epidemiological studies must confirm this hypothesis; and (ii)
the CTX-M-14 gene has disseminated among different E. coli
strains. Therefore, the possibility that a plasmid harboring the
CTX-M-14 gene or a mobile genetic element carrying this gene
had been disseminated in different E. coli strains cannot be
ruled out. A REP-PCR assay was performed as described in
Materials and Methods. This assay showed that most of the E.
coli strains were genetically unrelated (Fig. 1). Fifteen different
genotypes may be assigned to the 17 E. coli clinical strains
(isolates 3 and 4 and isolates 13 and 15 yielded the same band
patterns). This result therefore eliminated the possibility of
clonal dissemination of one epidemic E. coli strain.
Plasmid RFLP. Purified plasmids from transconjugants of
strains 1 to 17 (Table 2) were digested with HindIII, and the
resulting fragments were separated on 0.8% agarose gels (Fig.
2). The overall results showed a similarity between plasmids in
strains 1, 4, 5, 7, 9, 10, 12, 13, and 14 (RFLP pattern I in Table
3) obtained from the 17 E. coli strains, thus suggesting identity
in the plasmids harboring CTX-M-14 on these strains. How-
ever, strains 2, 3, 6, 8, 11, 15, 16, and 17 did not show a
similarity in their RFLP patterns, and their patterns were dif-
ferent from RFLP pattern I. Therefore, the CTX- M-14 gene
was harbored in different plasmids on these strains, and so the
possibility that a mobile genetic element might be involved in
the dissemination of the CTX-M-14 gene in these plasmids
cannot be ruled out.
Detection of the tnpA transposase gene. Plasmid DNAs from
the conjugants of the 17 E. coli clinical strains (strains 1 to 17
in Table 2) were subjected to PCR amplification with primers
which annealed to the tnpA gene, as described in Materials and
Methods. A positive band of 405 bp was obtained in all the
plasmid purifications (data not shown), suggesting that a pu-
tative functional transposon was present in all E. coli strains
and that this transposon may be involved in the mobilization of
the CTX-M-14 gene.
DISCUSSION
In 1992 (1, 2) a novel type of ESBL that conferred a high
level of resistance to cefotaxime but not to ceftazidime was
identified in some members of Enterobacteriaceae. This new
family of plasmid-mediated ESBLs of Ambler class A was
TABLE 2. MICs for the clinical strains included in this study
Isolate no. pI
MIC (g/ml) ofa:
AMX AMC FOX AT CTX CTX-CL CAZ CAZ-CL IMP MRP CEP
1 5.4, 8.0 256 4 8 4 24 0.094 1.5 0.25 0.25 0.016 2
2 8.0 256 4 2 2 24 0.047 1.0 0.094 0.25 0.016 2
3 8.0 256 6 4 3 16 0.064 1.0 0.25 0.25 0.016 2
3 (Tc)b 8.0 256 4 4 3 32 0.047 1.0 0.125 0.125 0.032 4
4 5.4, 8.0 256 4 2 0.75 16 0.023 0.5 0.064 0.094 0.012 1.5
5 5.4, 8.0 256 4 12 2 48 0.094 1.0 0.125 0.125 0.023 4
6 5.4, 8.0 256 4 4 2 24 0.047 0.75 0.125 0.19 0.016 2
7 8.0 256 4 2 2 24 0.032 1.0 0.064 0.19 0.012 1.5
8 8.0 256 4 4 2 16 0.064 1.0 0.125 0.125 0.016 4
9 5.4, 8.0 256 8 24 8 128 1.0 6.0 4.0 0.25 0.023 4
10 5.4, 8.0 256 6 12 2 64 0.094 1.0 0.125 0.125 0.016 4
11 5.4, 8.0 256 4 3 2 32 0.047 1.0 0.064 0.25 0.016 4
12 8.0 256 4 4 2 64 0.047 1.0 0.094 0.19 0.016 4
13 8.0 256 4 4 4 128 0.047 1.0 0.094 0.125 0.012 2
14 8.0 256 4 4 2 48 0.064 1.5 0.19 0.125 0.012 4
15 8.0 256 4 3 1.5 128 0.047 1.0 0.125 0.19 0.016 4
16 5.4, 8.0 256 4 4 2 16 0.064 1.0 0.19 0.19 0.023 2
17 8.0 256 4 4 2 24 0.064 1.0 0.125 0.125 0.012 2
18 5.4, 8.5 256 4 2 8 24 1 32 4 0.25 0.032 0.38
19 5.4 256 16 16 24 0.5 0.19 32 0.75 0.25 0.032 2
20 5.4 256 2 1 0.5 0.016 0.016 12 0.064 0.19 0.023 0.032
21 5.4 256 4 12 6 0.5 0.016 32 0.19 0.125 0.023 0.75
22 9.0 256 4 2 4 256 0.047 6 0.094 0.125 0.016 8
23 9.0 256 12 256 256 256 1.0 32 4 0.125 0.064 128
24 9.0 256 12 256 256 256 1.0 32 4 0.125 0.047 128
25 5.9 256 4 2 1 2 0.094 2 0.19 0.5 0.032 0.094
26 5.4, 5.9 256 4 8 6 0.19 0.047 32 0.125 0.125 0.016 0.5
27 7.6 256 8 4 0.125 0.064 0.032 4 0.19 0.19 0.032 0.5
28c 7.4 256 4 1 6 24 0.016 32 0.19 0.19 0.032 3
29c 7.9 256 4 12 6 0.5 0.064 32 0.19 0.125 0.023 0.75
30c 7.4 256 6 2 1 1 0.047 1.5 0.125 0.19 0.032 0.094
E. coli TG1 3 3 2 0.047 0.023 0.023 0.064 0.064 0.125 0.032 0.094
E. coli TG1 (pC)d 8.0 256 6 2 48 256 0.064 4 0.125 0.19 0.023 64
a AMX, amoxicillin; AMC, amoxicillin-clavulanic acid; FOX, cefoxitin; AT, aztreonam; CTX, cefotaxime; CTX-CL, cefotaxime-clavulanic acid; CAZ, ceftazidime;
CAZ-CL, ceftazidime-clavulanic acid; IMP, imipenem; MRP, meropenem; CEP, cefepime.
b This isolate corresponds to the transconjugant of clinical strain 3.
c This isolate corresponds to K. pneumoniae.
d E. coli transformed with plasmid pC, which carries the CTX-M-14 gene.
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assigned to the cefotaximase (CTX-M) family. Cefotaximases
(CTX-M) have been detected mainly in South America, East-
ern Europe, Japan, Spain, Kenya, and France (3, 13, 15, 17,
22).
The family of the CTX-M-type ESBLs comprises several
members belonging to four major phylogenetic trees on the
basis of their amino acid sequence similarities (4): the CTX-
M-1 group (CTX-M-1, CTX-M-3, and CTX-M-10), the CTX-
M-2 group (CTX-M-2, Toho-1, CTX-M-4, CTX-M-5, and
CTX-M-6), the CTX-M-9 group (CTX-M-9 and Toho-2),
and the CTX-M-8 group. The CTX-M-14 -lactamase is an
Ala231-Val mutant of CTX-M-9; therefore, it may be assigned
to the CTX-M-9 group.
We have detected the CTX-M-14 -lactamase for the first
FIG. 1. REP-PCR of the 17 E. coli strains and 2 genetically unrelated E. coli controls (C1 and C2). The strain numbers are shown above the
gel. Mw (molecular size markers) corresponds to the 1-kb DNA ladder (Promega, Madison, Wis.).
FIG. 2. Plasmid RFLP obtained by HindIII digestion with plasmid purifications of the transconjugants of the 17 E. coli strains. The strain
numbers are shown above the gel. Mw (molecular size markers) corresponds to the lambda DNA HindIII digest and bacteriophage 174 HaeIII
digest (Fynnzymes OY).
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time in Spain. This -lactamase has previously been described
in China, Korea, and France (8, 11, 16, 19).
As described above, the CTX-M-14 gene is plasmid medi-
ated; indeed, we detected it in the plasmids of the 15 different
genotypes of E. coli strains. The plasmid fingerprints yielded 9
different patterns; therefore, 9 of the 17 profiles were identical.
This result suggests that the spreading of this plasmid among
different E. coli strains was important in the dissemination of
the CTX-M-14 gene. However, in the other eight E. coli
strains, different plasmids were detected, as shown by restric-
tion analysis. This result implies some kind of mobilization of
the CTX-M-14 gene in the different E. coli strains in addition
to the horizontal transfer. The analysis of the CTX-M-14 up-
stream region showed the presence of the transposase gene
(tnpA) of the insertion sequence named ISEcp-1 in all plasmids
detected in the E. coli strains. It has previously been suggested
that the ISEcp-1 element could be associated with the mobility
of the CTX-M genes (11). Therefore, the possibility that the
ISEcp-1 insertion sequence can be associated with the spread-
ing of the CTX-M-14 genes in our E. coli strains cannot be
ruled out. In fact, this is the only genetic element we have
found associated with the high dissemination of the CTX-M-14
gene.
These 17 E. coli strains (15 genotypes) caused infections in
17 patients. In 15 patients the E. coli strain harboring CTX-
M-14 caused urinary tract infections whereas in the other two
they caused wound infections. Furthermore, most patients had
underlying diseases and, interestingly, no hospital admission
was noted in the medical records of 7 patients. Thus, on the
basis of these data, we may assume the possible existence of
outpatients with bacterial strains causing infections harboring
antibiotic resistance mechanisms. Therefore, the data present-
ed here raise the hypothesis that microorganisms with antibi-
otic resistance mechanisms can be present in patients in the
community. Another interesting issue is that no apparent con-
tacts between the 17 patients occurred. Indeed, most inpatients
were admitted to different hospital wards of the hospital com-
plex. The outpatients live in different areas far away from each
other. With the current data, how can we explain the presence
of up to 62% of the ESBL-producing strains as harboring the
CTX-M-14 gene? Several reports have been published describ-
ing the detection of CTX-M-type enzymes in different areas
worldwide. Here we report a practical study showing that
CTX-M-type -lactamases are highly disseminated; indeed,
they are replacing the TEM and SHV derivative -lactamases
(9). The reasons why this is happening remain to be elucidated.
In a hospital environment, spreading between patients can
be easy when a bacterium with an antibiotic resistance mech-
anism has been established, especially if this mechanism is
associated with mobile genetic elements. However, we report
here that seven patients from whom bacterial strains harboring
ESBL were isolated never had contact with the hospital envi-
ronment before the clinical E. coli isolation. Further epidemi-
ological studies need to be performed to explain these data.
In summary, we have found a high prevalence of the CTX-
M-14 -lactamase in the northwest area of Spain. On the basis
of these data, the empirical administration of cefotaxime in
serious infections should be avoided in order to prevent clinical
complications. In addition, we alert the medical community of
the increase of these -lactamases worldwide.
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